Altamira Therapeutics Receives Letter From Nasdaq Qualifications Department That It Is No Longer In Compliance
Altamira Therapeutics Receives Letter From Nasdaq Qualifications Department That It Is No Longer In Compliance
Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that it no longer complied with Rule 5550(a)(2) of Nasdaq's Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company's listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. The letter stated that the Company is not eligible for any cure period due to the fact that the Company effectuated one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. The Company intends to appeal this determination to a hearing panel (the "Panel"). The hearing request will result in a stay of any suspension or delisting action pending the hearing. There can be no assurance that the Panel will grant the Company's request for continued listing or that any extension will be granted by the Panel.
Altamira Therapeutics Ltd.（"Altamira"或"公司"）（纳斯达克股票代码：CYTO）今日宣布，于2024年9月30日收到了纳斯达克股份市场有限责任公司（"纳斯达克"）上市资格部门的一封信，内容指出公司不再符合纳斯达克的上市规则第5550(a)(2)条的规定。该规定要求上市证券维持每股最低1.00美元的最低买盘价格，因为该公司上市证券的买盘价格在2024年8月16日至2024年9月27日期间的前30个连续业务日内收于1.00美元以下。信函指出，由于该公司在过去两年内实施了一项或多项拆股并股业务，总比率为250股或更多合一。公司打算向一个听证小组（"小组"）上诉这一决定。提出听证请求将导致停止任何暂停或摘牌行动，等待听证。无法保证小组会批准公司继续上市的要求，或者小组会批准延长任何期限。
